PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. Electronic address: james.clark12@nhs.net.\', \'Commercial Medicines Directorate, NHS England & NHS Improvement, Skipton House, London, UK.\', \'Medical Directorate, NHS England & NHS Improvement, Skipton House, London, UK; Cancer Research UK Research Centre, University of Southampton, Southampton, UK.\', \'Cancer Research UK and UCL Cancer Trials Centre, Cancer Institute, University College London, London, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1470-2045(20)30619-710.1016/S1470-2045(20)30619-7
?:doi
?:hasPublicationType
?:journal
  • The Lancet. Oncology
is ?:pmid of
?:pmid
?:pmid
  • 33253639
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33253639>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33253639>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all